RIGL Rigel Pharmaceuticals Inc

Price (delayed)

$3.83

Market cap

$654.36M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.05

Enterprise value

$604.47M

Rigel Pharmaceuticals, Inc., is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with hematologic disorders, cancer and rare ...

Highlights
The net income has surged by 69% year-on-year and by 33% since the previous quarter
Rigel Pharmaceuticals's EPS has surged by 64% YoY and by 29% QoQ
RIGL's equity is down by 13% from the previous quarter but it is up by 8% YoY
The quick ratio has contracted by 18% from the previous quarter and by 4.3% YoY

Key stats

What are the main financial stats of RIGL
Market
Shares outstanding
170.85M
Market cap
$654.36M
Enterprise value
$604.47M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
9.57
Price to sales (P/S)
4.52
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.19
Earnings
Revenue
$144.12M
EBIT
-$3.83M
EBITDA
-$6.76M
Free cash flow
-$970,000
Per share
EPS
-$0.05
Free cash flow per share
-$0.01
Book value per share
$0.4
Revenue per share
$0.85
TBVPS
$1.18
Balance sheet
Total assets
$201.6M
Total liabilities
$133.49M
Debt
$34.94M
Equity
$68.11M
Working capital
$124.65M
Liquidity
Debt to equity
0.51
Current ratio
3.09
Quick ratio
2.87
Net debt/EBITDA
7.38
Margins
EBITDA margin
-4.7%
Gross margin
99.4%
Net margin
-5.4%
Operating margin
-2.7%
Efficiency
Return on assets
-4.8%
Return on equity
-13.4%
Return on invested capital
-3.4%
Return on capital employed
-2.7%
Return on sales
-2.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

RIGL stock price

How has the Rigel Pharmaceuticals stock price performed over time
Intraday
-0.26%
1 week
-4.25%
1 month
5.22%
1 year
53.2%
YTD
9.43%
QTD
-11.75%

Financial performance

How have Rigel Pharmaceuticals's revenue and profit performed over time
Revenue
$144.12M
Gross profit
$143.22M
Operating income
-$3.9M
Net income
-$7.73M
Gross margin
99.4%
Net margin
-5.4%
The operating margin has soared by 89% YoY and by 56% from the previous quarter
RIGL's operating income has surged by 85% year-on-year and by 53% since the previous quarter
RIGL's net margin has soared by 77% YoY and by 37% QoQ
The net income has surged by 69% year-on-year and by 33% since the previous quarter

Growth

What is Rigel Pharmaceuticals's growth rate over time

Valuation

What is Rigel Pharmaceuticals stock price valuation
P/E
N/A
P/B
9.57
P/S
4.52
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.19
Rigel Pharmaceuticals's EPS has surged by 64% YoY and by 29% QoQ
The price to book (P/B) is 57% more than the 5-year quarterly average of 6.1 but 12% less than the last 4 quarters average of 10.9
RIGL's equity is down by 13% from the previous quarter but it is up by 8% YoY
The stock's price to sales (P/S) is 92% less than its 5-year quarterly average of 55.7 and 3.8% less than its last 4 quarters average of 4.7
Rigel Pharmaceuticals's revenue has increased by 33% YoY and by 8% QoQ

Efficiency

How efficient is Rigel Pharmaceuticals business performance
Rigel Pharmaceuticals's return on sales has surged by 88% YoY and by 55% QoQ
RIGL's return on invested capital has surged by 85% year-on-year and by 51% since the previous quarter
The return on assets has surged by 72% year-on-year and by 38% since the previous quarter
The ROE has soared by 65% year-on-year and by 34% since the previous quarter

Dividends

What is RIGL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RIGL.

Financial health

How did Rigel Pharmaceuticals financials performed over time
Rigel Pharmaceuticals's total assets is 51% more than its total liabilities
The total liabilities has soared by 78% YoY but it has contracted by 3.1% from the previous quarter
Rigel Pharmaceuticals's total assets has increased by 46% YoY but it has decreased by 7% from the previous quarter
RIGL's debt is 49% lower than its equity
RIGL's debt to equity is down by 25% YoY but it is up by 9% QoQ
RIGL's debt is down by 19% YoY and by 6% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.